gdc
Submit Your Story
Subscribe

ASCO 2021

Can Immunotherapy Be a Cure in Advanced Bladder or Kidney Cancer?
ASCO 2021Bladder Cancer
Can Immunotherapy Be a Cure in Advanced Bladder or Kidney Cancer?
By Meg Barbor, MPH
Web Exclusives
Adding Tukysa to the Treatment Regimen Extends Survival in Patients with HER2-Positive Metastatic Breast Cancer
ASCO 2021Breast Cancer
Adding Tukysa to the Treatment Regimen Extends Survival in Patients with HER2-Positive Metastatic Breast Cancer
By Chase Doyle
Web Exclusives
Hot Topics from the 2021 American Society of Clinical Oncology Conference
Issue IntroductionsASCO 2021
Hot Topics from the 2021 American Society of Clinical Oncology Conference
By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
ASCO 2021 Highlights
Immunotherapy Combination plus Radiation a Potential Alternative to Radical Surgery in Patients with Localized Muscle-Invasive Bladder Cancer
Bladder CancerASCO 2021
Immunotherapy Combination plus Radiation a Potential Alternative to Radical Surgery in Patients with Localized Muscle-Invasive Bladder Cancer
By Chase Doyle
ASCO 2021 Highlights
Using Imfinzi Before Chemotherapy Improves Outcomes in Patients with Early-Stage Triple-Negative Breast Cancer
Breast CancerASCO 2021
Using Imfinzi Before Chemotherapy Improves Outcomes in Patients with Early-Stage Triple-Negative Breast Cancer
By Meg Barbor, MPH
ASCO 2021 Highlights
Lynparza, a PARP Inhibitor, Extends Disease-Free Survival in Patients with Early-Stage Breast Cancer and BRCA Mutation
Breast CancerASCO 2021
Lynparza, a PARP Inhibitor, Extends Disease-Free Survival in Patients with Early-Stage Breast Cancer and BRCA Mutation
By Wayne Kuznar
ASCO 2021 Highlights
Balstilimab a Promising New Immunotherapy for Patients with Advanced Cervical Cancer, Regardless of PD-1/PD-L1 Expression
Cervical CancerASCO 2021
Balstilimab a Promising New Immunotherapy for Patients with Advanced Cervical Cancer, Regardless of PD-1/PD-L1 Expression
By Wayne Kuznar
ASCO 2021 Highlights
Immunotherapy After Surgery May Be a New Standard of Care for Patients with Advanced Kidney Cancer
Kidney CancerASCO 2021
Immunotherapy After Surgery May Be a New Standard of Care for Patients with Advanced Kidney Cancer
By Phoebe Starr
ASCO 2021 Highlights
Tecartus, a CAR T-Cell Therapy, Leads to Complete Remissions in Patients with Acute Lymphoblastic Leukemia
LeukemiaASCO 2021
Tecartus, a CAR T-Cell Therapy, Leads to Complete Remissions in Patients with Acute Lymphoblastic Leukemia
ASCO 2021 Highlights
Lumakras First Therapy Targeting KRAS Mutation in Patients with Non–Small-Cell Lung Cancer
Lung CancerASCO 2021
Lumakras First Therapy Targeting KRAS Mutation in Patients with Non–Small-Cell Lung Cancer
By Phoebe Starr
ASCO 2021 Highlights
  • 1
  • 2
Page 1 of 2
Results 1 - 10 of 20

Subscribe to CONQUER™: the patient voice™ magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest